FR2929615B1 - Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. - Google Patents

Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Info

Publication number
FR2929615B1
FR2929615B1 FR0852185A FR0852185A FR2929615B1 FR 2929615 B1 FR2929615 B1 FR 2929615B1 FR 0852185 A FR0852185 A FR 0852185A FR 0852185 A FR0852185 A FR 0852185A FR 2929615 B1 FR2929615 B1 FR 2929615B1
Authority
FR
France
Prior art keywords
obesity
diabetes
treatment
glycoside compounds
aryl glycoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0852185A
Other languages
English (en)
Other versions
FR2929615A1 (fr
Inventor
Deliencourt Godefroy Geraldine Castelot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tfchem SARL
Original Assignee
Tfchem SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tfchem SARL filed Critical Tfchem SARL
Priority to FR0852185A priority Critical patent/FR2929615B1/fr
Priority to EP09727801.4A priority patent/EP2280983B9/fr
Priority to US12/935,468 priority patent/US8486897B2/en
Priority to PCT/EP2009/053970 priority patent/WO2009121939A2/fr
Priority to CA2720011A priority patent/CA2720011C/fr
Publication of FR2929615A1 publication Critical patent/FR2929615A1/fr
Application granted granted Critical
Publication of FR2929615B1 publication Critical patent/FR2929615B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0852185A 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. Expired - Fee Related FR2929615B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0852185A FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
EP09727801.4A EP2280983B9 (fr) 2008-04-02 2009-04-02 Composés c-aryl glycosides pour le traitement du diabète et de l'obésité
US12/935,468 US8486897B2 (en) 2008-04-02 2009-04-02 C-aryl glycoside compounds for the treatment of diabetes and obesity
PCT/EP2009/053970 WO2009121939A2 (fr) 2008-04-02 2009-04-02 Composés c-aryl glycosides pour le traitement du diabète et de l'obésité
CA2720011A CA2720011C (fr) 2008-04-02 2009-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0852185A FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Publications (2)

Publication Number Publication Date
FR2929615A1 FR2929615A1 (fr) 2009-10-09
FR2929615B1 true FR2929615B1 (fr) 2010-12-17

Family

ID=39500050

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0852185A Expired - Fee Related FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Country Status (5)

Country Link
US (1) US8486897B2 (fr)
EP (1) EP2280983B9 (fr)
CA (1) CA2720011C (fr)
FR (1) FR2929615B1 (fr)
WO (1) WO2009121939A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000637A (es) 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN103649033B (zh) 2011-05-26 2016-02-24 Tf化学公司 芳基、杂芳基、o-芳基和o-杂芳基碳环糖家族
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
US10414787B2 (en) 2013-03-14 2019-09-17 Mars, Incorporated Flavor composition containing HMG glucosides
BR112018074716A2 (pt) 2016-06-02 2019-03-12 Sanofi conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose
WO2019106122A1 (fr) 2017-12-01 2019-06-06 Sanofi Nouveaux conjugués constitués d'un agent pharmaceutique et d'une fraction pouvant se lier à une protéine de détection du glucose
EP4074317A1 (fr) 2021-04-14 2022-10-19 Bayer AG Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
FR2842810B1 (fr) 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
WO2005012242A2 (fr) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Benzimidazole-, benztriazole- et benzimidazolone-o-glucosides substitues
US20070135357A1 (en) * 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
FR2900405B1 (fr) 2006-04-27 2013-11-29 Inst Nat Sciences Appliq Nouveaux composes c-glycosides monofluores, leurs procedes de preparation et leurs applications
US8450286B2 (en) 2008-03-18 2013-05-28 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof

Also Published As

Publication number Publication date
EP2280983A2 (fr) 2011-02-09
CA2720011A1 (fr) 2009-10-08
CA2720011C (fr) 2016-07-05
US8486897B2 (en) 2013-07-16
FR2929615A1 (fr) 2009-10-09
WO2009121939A3 (fr) 2010-11-11
WO2009121939A2 (fr) 2009-10-08
EP2280983B9 (fr) 2021-06-09
EP2280983B1 (fr) 2013-03-13
US20110034402A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
FR2929615B1 (fr) Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
IL254157A0 (en) 3–14–eta antibodies and their uses for the diagnosis and treatment of arthritis
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
EP2103628A4 (fr) Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
EP2041317A4 (fr) Procédés et compositions à base de micro-arn pour le diagnostic et le traitement de maladies apparentées au cancer du colon
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
EP3318562A3 (fr) Dérivés de benzylbenzène et procédés d'utilisation
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
PL2018184T3 (pl) Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
SMT201500190B (it) Composizioni comprendenti un anticorpo a p2-specifico o un suo frammento per l'uso nel trattamento del diabete, intolleranza al glucosio o insulino-resistenza indotta dall'obesita'
HK1197052A1 (en) Low scale potential water treatment
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.
FR2922109B1 (fr) Composition pharmaceutique ou dietetique pour inhiber l'absorption intestinale du sucre.
FR2906469B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme
FR2916345B1 (fr) Dispositif pour le traitement du larmoiement de l'oeil
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
EP2123676A4 (fr) Diagnostic et traitement de cancers utilisant un anticorps anti-prg-3

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20151231